Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 15

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 15
---
 of, the terms “material,” “Material Adverse Effect” and words of similar import shall be disregarded and given no effect plus (ii) any and all losses               
 incurred or accrued from the Closing Date through the six (6) month anniversary of the Closing and any estimated losses to be incurred in connection with any of the matters discussed in the covenant regarding stockholder litigation as   
 reasonably determined or estimated by TuHURA, including any reasonable attorneys’ fees and disbursements;                                                                                                                                    |

| • |     | “In-the-Money Company                                                                                                                                                                      
 Stock Option” means a Kineta Stock Option that is unexpired, unexercised and outstanding immediately prior to the Effective Time and has a per share exercise price that is $0.64 or less; |

| • |     | “Initial Per Share Stock Consideration” refers to the quotient of (i) the Initial Share                  
 Consideration divided by (ii) Kineta Fully Diluted Common Stock, rounded down to six (6) decimal places; |

| • |     | “Initial Share Consideration” means the number of shares of TuHURA Common Stock equal to the                                                                                                                                         
 quotient of (i) the difference of (A) Sixteen Million Five Hundred Thousand Dollars ($16,500,000) minus (B) the Deficit Cash Consideration, if any, divided by (ii) the TuHURA Share Value, rounded down to the nearest whole share; |

4

| • |     | “Intended Tax Treatment” has the meaning ascribed to it in “Material U.S. Federal Income 
 Tax Consequences of the Mergers”;                                                        |

| • |     | “KCP506 Asset Sale” refers to the sale of Kineta’s asset and properties related to KCP506,                                    
 a product candidate developed by Kineta for the treatment of pain, to Pacira pursuant to the Pacira Asset Purchase Agreement; |

| • |     | “Kineta” means Kineta, Inc., a Delaware corporation; |

| • |     | “Kineta Chronic Pain” refers to Kineta Chronic Pain, LLC; |

| • |     | “Kineta Adjournment Proposal” refers to the proposal for Kineta stockholders to approve the                                                                                                                                                        
 adjournment of the Kineta special meeting, if necessary or appropriate, (i) to solicit additional proxies if there are insufficient shares of Kineta Common Stock represented (either in person or by proxy) and voting to obtain the Kineta       
 Stockholder Approval or